Acer Therapeutics — Investor Presentation (May 2022)
33 slides from Acer Therapeutics's investor presentation, May 16, 2022
Slide 1: Corporate Presentation
Developing Therapeutics for the Treatment of Serious Rare and Life-Threatening Diseases with Significant Unmet Medical Needs Corporate Presentation May 16, 2022 Nasdaq: ACER Exhibit 99.2
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in
Slide 3: Corporate Overview
Corporate Overview Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious rare and life-threatening diseases with significant unmet medical needs Offices: Newton, MA and Bend, OR Headcount: 43 Founded: December 2013 Public: September 20
Slide 4: Investment Highlights
4 Investment Highlights ACER Acer’s pipeline includes four investigational programs: ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD) ACER-801 (osanetant) for the treatment of induced
Slide 5: Clinical Pipeline
5 Clinical Pipeline ACER $ Additional capital required to support planned ACER-001 (MSUD) and EDSIVO™ clinical trials beyond Q3 2022, and to fund ACER-2820 program going forward $ PDUFA: June 5, 2022 $ $
Slide 6: Urea cycle disorders (UCDs) overview
Urea cycle disorders (UCDs): a group of metabolic genetic diseases that lead to toxic build-up of ammonia (NH4+) 6 Current Treatment Options Disease Overview The Opportunity ACER-001 Profile Overview 1 Payer claims data on file 2 https://ir.horizontherapeutics.com/static-files/47f395cb-4d8e-47a7-ba2
Slide 7: Urea Cycle Disorders symptoms
Newborns with severe urea cycle disorders become significantly ill with symptoms that mimic sepsis -- failure to feed, lethargy, respiratory distress, seizures and ultimately coma Children and adults with milder (or partial) urea cycle enzyme deficiencies may go years without a diagnosis, until a tr
Slide 8: ACER-001 Mechanism of Action
8 Berry S, et al. Molecular Genetics and Metabolism 125 (2018) 251–257. ACER-001 Mechanism of Action NH4+ α-Ketoglutarate Glutamate Glutamine GPB PBA Buphenyl ® (sodium phenylbutyrate) PAA PAGN Ravicti® (glycerol phenylbutyrate) Oral Liquid Ester hydrolysis/ Pancreatic Lipases β-oxidation Urine Excr
Slide 9: ACER-001 Unmet Need
9 ACER-001 Unmet Need BUPHENYL®: Aversive taste and odor1; considered unpalatable by some patients2 64% of patients reported it is difficult to take because of taste2 Physicians reported that 25-33% of patients took less than target dose due to tolerability2 Only 25% of patients indicated that they
Slide 10: ACER-001 Product Differentiation
10 * Subject to FDA approval ** Shchelochkov et al., Molecular Genetics and Metabolism Reports 8 (2016) 43-47 *** RAVICTI® and BUPHENYL® pppy is based on patient weight and WAC price ACER-001 Product Differentiation
Slide 11: ACER-001 Value Proposition
11 ACER-001 Value Proposition ACER-001 Novel polymer-coated formulation for oral administration Designed to minimize bitter taste1 Convenient packaging + additional dosing options 505(b)(2) NDA submission: bioequivalence trials showed ACER-001 has similar relative bioavailability to sodium phenylbut
Slide 12: ACER-001 IP / Exclusivities
12 ACER-001 IP / Exclusivities IP: Issued patents: US Patent 11,154,521 covering claims re: formulation compositions of matter Expires in 2036 US Patent 11,202,767 covering claims re: certain methods of use Expires in 2036 US Patent 10,092,532 covering claims re: methods of modulation of branched ch
Slide 13: Agreement with Relief Therapeutics
Signed Collaboration and License Agreement Q1 2021 To date, Acer has received $35.0M of funding Acer retained development and commercialization rights in the U.S., Canada, Brazil, Turkey and Japan Split net profits from Acer’s territories (60% to Relief; 40% to Acer) Relief licensed rights for the r
Slide 14: ACER-801 Vasomotor symptoms overview
Vasomotor symptoms (VMS) are caused by a decrease in estrogen signaling in the brain, resulting in menopausal-like symptoms (hot flashes, night sweats, etc.) 14 ACER-801 Current Treatment Options Disease Overview The Opportunity ACER-801 Profile Overview 1 Rada G., et al. Cochrane Database Syst Rev.
Slide 15: Vasomotor Symptoms (VMS)
VMS, typically comprised of hot flashes and night sweats, are associated with decreases in reproductive hormones commonly associated with menopause (e.g. MR-VMS) 15 Vasomotor Symptoms (VMS) Roth A, et al. The Oncologist, Oct 2003, vol.8 no.5 474-487. Levine B. http://www.everydayhealth.com/menopause
Slide 16: Induced Vasomotor Symptoms (iVMS)
16 Induced Vasomotor Symptoms (iVMS) Women with HR+ Breast Cancer (CaB) receiving Tamoxifen 84% of women experienced hot flashes1 80% experienced night sweats 60% experienced severe symptoms Symptoms persisted throughout 5 years of treatment and were mainly attributed to tamoxifen After 4.5 years, 4
Slide 17: ACER-801 Mechanism of Action
Neurokinin B (NKB) belongs to a group of neuropeptides, called tachykinins or neurokinins, that includes substance-P (SP), neurokinin A (NKA), and two N-terminally extended forms of NKA, neuropeptide g and neuropeptide K The biological effects of tachykinins are mediated through specific receptors d
Slide 18: Clinical POC in VMS: NK3R Antagonist
18 Clinical POC in VMS: NK3R Antagonist Depypere H, et al. ENDO2017 Fezolinetant is a NK3R antagonist being developed by Astellas for moderate-to-severe VMS ACER-801 At Week 4: fezolinetant group: 14/40 patients have ZERO hot flash placebo group: 2/40 patients have ZERO hot flash Average Daily Hot F
Slide 19: Clinical POC in VMS: NK1,3R Antagonist
19 Clinical POC in VMS: NK1,3R Antagonist Trower M, et al. Menopause. 2020 May; 27(5): 498–505. Elinzanetant (NT-814) is a dual NK1,3R antagonist for the treatment of vasomotor symptoms in postmenopausal women ACER-801 % change from baseline Hot flash frequency Hot flash severity Placebo MLE4901 Hot
Slide 20: ACER-801 Development Plan
Q1 2022: Began patient enrollment in Phase 2a, randomized, double-blind, placebo-controlled, dose-ranging trial (NCT05325775) in Q1 2022: Primary objective: Evaluate the safety profile of ACER-801 at different doses Evaluate the pharmacokinetic (PK) profile of ACER-801 at different doses Secondary o
Slide 21: EDSIVO Overview and Current Treatment Options
Current Treatment Options Autosomal dominant connective tissue disorder of collagen synthesis caused by mutations in the COL3A1 gene for type III procollagen Characterized by arterial aneurysms, dissections and/or ruptures in arteries and hollow organs (intestines, uterus, lungs, etc.) Often fatal:
Slide 22: Vascular Ehlers-Danlos Syndrome (vEDS)
Ehlers-Danlos syndrome (EDS) is a group of hereditary disorders of connective tissue vEDS (EDS type IV) is the severe subtype: Characterized by aneurysms, dissections and/or ruptures Vascular Hollow Organs (e.g. gastrointestinal, uterine) Autosomal dominant (50%); spontaneous mutations (50%) Diagnos
Slide 23: EDSIVO BBEST Trial Efficacy
Efficacy: 76% reduction in the risk of fatal or nonfatal cardiac or arterial events in COL3A1+ EDSIVO™ patients vs. control group over mean follow-up of 47 months 75% reduction in risk of primary (cardiac or arterial events) and secondary (intestinal or uterine rupture) events in COL3A1+ EDSIVO™ pat
Slide 24: DiSCOVER trial design
DiSCOVER (Decentralized Study of Celiprolol on vEDS-related Event Reduction) trial design:* A Phase 3, U.S.-based, randomized, double-blind, decentralized (virtual) clinical trial to compare the efficacy of celiprolol to placebo in the treatment of patients with COL3A1-positive vEDS Primary objectiv
Slide 25: ACER-2820 Profile
Host-directed therapy – restores the cellular stress response, blocking ribosome biogenesis and translation-elongation of viral mRNA in infected cells Mechanism of Action Potential treatment for DNA and RNA-replicating viruses, including coronavirus, filovirus, flavivirus, herpesvirus, togavirus, ar
Slide 26: ACER-2820 Broad-spectrum, Antiviral Activity
26 ACER-2820 Broad-spectrum, Antiviral Activity
Slide 27: ACER-2820 Nanomolar Potency In Vitro
27 ACER-2820 Nanomolar Potency In Vitro EC50 = concentration of a drug that gives half-maximal response. IC50 = concentration of an inhibitor where the response is reduced by half CC50 = 50% cytotoxic concentration *EC50 / CC50 values = μM (unless otherwise noted) **For reference, the EC50 of remdes
Slide 28: ACER-2820 In Vivo Efficacy Data
28 ACER-2820 In Vivo Efficacy Data A b C B SJL mice Number of ZIKV particles per 1 μg RNA sample 101 102 103 104 Emetine - + Day 0 Day 6 n.d. * Serum viral load (NS1 ng/mL) -10000 1000 2000 3000 Ifnar1 -/- mice VC E1 E2 MOCK % Survival BALB/c mice DPBS emetine 1 mg/kg Post-infection (Days) 0 20 40 6
Slide 29: ACER Financial Overview
29 Cash as of March 31, 2021: $20.8M Expected to have sufficient capital to fund current operations into Q3 2022 If ACER-001 receives U.S. FDA approval, $42.5M expected to be funded through loan from Marathon, extending available capital for planned operations into H2 2023* Capitalization as of May
Slide 30: Reference Slides
Reference Slides 30
Slide 31: Leadership Team
Leadership Team Chris Schelling 23 years; strategic commercial dev. & orphan BiOMARIN a 1 Quarts, MD 20+ years; clin, dev., medical & regulatory affairs | BIOMARIN Harr ry Falmin 25+ years; corporate & finance experience Novelos _ Seibt lal Officer |" 24 YeArS: Sales, market access & product launch
Slide 32: MSUD Overview
MSUD is an inborn error of Branched-chain Amino Acid (BCAA) – leucine, isoleucine, valine – metabolism Caused by deficiency of the mitochondrial Branched-chain Keto Acid Dehydrogenase complex (BCKDC) ~800 patients in U.S., ~3,000 patients worldwide MSUD Family Support Group has >500 patients Part of
Slide 33: ACER-001 MSUD: Clinical POC
33 ACER-001 MSUD: Clinical POC Study Design: Open label pilot study1 at Baylor College of Medicine – 3 healthy and 5 MSUD subjects with late onset disease 3 days of steady-state protein diet*; then 3 days of NaPB + diet* BCAAs and BCKAs determined at day 3 of each study period (4 time points) Result